Free Trial

Leap Therapeutics (LPTX) Competitors

Leap Therapeutics logo
$0.29 -0.01 (-2.80%)
Closing price 04:00 PM Eastern
Extended Trading
$0.30 +0.01 (+2.43%)
As of 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LPTX vs. IMMX, VHAQ, ANRO, ACHL, RPTX, ASRT, CRVO, QNCX, RENB, and VTGN

Should you be buying Leap Therapeutics stock or one of its competitors? The main competitors of Leap Therapeutics include Immix Biopharma (IMMX), Viveon Health Acquisition (VHAQ), Alto Neuroscience (ANRO), Achilles Therapeutics (ACHL), Repare Therapeutics (RPTX), Assertio (ASRT), CervoMed (CRVO), Quince Therapeutics (QNCX), Renovaro (RENB), and VistaGen Therapeutics (VTGN). These companies are all part of the "pharmaceutical products" industry.

Leap Therapeutics vs. Its Competitors

Leap Therapeutics (NASDAQ:LPTX) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Immix Biopharma's return on equity of -130.02% beat Leap Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Leap TherapeuticsN/A -162.15% -120.05%
Immix Biopharma N/A -130.02%-86.33%

Leap Therapeutics presently has a consensus target price of $3.38, indicating a potential upside of 1,071.88%. Immix Biopharma has a consensus target price of $7.00, indicating a potential upside of 190.46%. Given Leap Therapeutics' higher possible upside, equities research analysts plainly believe Leap Therapeutics is more favorable than Immix Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Leap Therapeutics
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Immix Biopharma
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by insiders. Comparatively, 55.4% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Leap Therapeutics has a beta of -0.28, indicating that its share price is 128% less volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of 0.24, indicating that its share price is 76% less volatile than the S&P 500.

Immix Biopharma is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Leap TherapeuticsN/AN/A-$67.56M-$1.70-0.17
Immix BiopharmaN/AN/A-$21.61M-$0.70-3.44

In the previous week, Immix Biopharma had 1 more articles in the media than Leap Therapeutics. MarketBeat recorded 1 mentions for Immix Biopharma and 0 mentions for Leap Therapeutics. Leap Therapeutics' average media sentiment score of 1.89 beat Immix Biopharma's score of 0.94 indicating that Leap Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Leap Therapeutics Very Positive
Immix Biopharma Positive

Summary

Immix Biopharma beats Leap Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Leap Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LPTX vs. The Competition

MetricLeap TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.28M$2.88B$5.54B$8.87B
Dividend YieldN/A2.64%5.39%4.10%
P/E Ratio-0.1721.3126.1719.90
Price / SalesN/A278.47414.67113.66
Price / CashN/A41.4736.1356.90
Price / Book0.327.518.055.38
Net Income-$67.56M-$55.05M$3.15B$248.50M
7 Day Performance2.86%2.45%1.85%2.97%
1 Month Performance-19.67%7.33%4.81%6.02%
1 Year Performance-82.96%5.38%34.86%20.39%

Leap Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LPTX
Leap Therapeutics
2.3 of 5 stars
$0.29
-2.8%
$3.38
+1,071.9%
-84.2%$12.28MN/A-0.1740Positive News
Gap Down
IMMX
Immix Biopharma
3.6778 of 5 stars
$2.23
-0.4%
$7.00
+213.9%
+3.3%$62.44MN/A-3.199
VHAQ
Viveon Health Acquisition
N/A$11.00
flat
N/AN/A$62.26MN/A0.002High Trading Volume
ANRO
Alto Neuroscience
2.3506 of 5 stars
$2.37
+5.1%
$8.50
+259.4%
-80.5%$60.91MN/A0.00N/ANews Coverage
ACHL
Achilles Therapeutics
N/A$1.48
flat
N/AN/A$60.83MN/A-0.90250
RPTX
Repare Therapeutics
2.5022 of 5 stars
$1.41
flat
$4.50
+219.1%
-57.4%$60.48M$53.48M-0.47180Positive News
ASRT
Assertio
1.7563 of 5 stars
$0.63
+0.3%
$2.75
+335.7%
-46.1%$60.26M$124.96M-1.9720
CRVO
CervoMed
3.3958 of 5 stars
$6.52
-4.8%
$27.63
+323.7%
-63.2%$59.61M$9.74M0.004News Coverage
QNCX
Quince Therapeutics
3.3036 of 5 stars
$1.32
+1.5%
$8.00
+506.1%
+109.7%$59.11MN/A-0.9560Positive News
RENB
Renovaro
1.1848 of 5 stars
$0.37
+7.9%
N/A-82.6%$58.76MN/A0.0020News Coverage
High Trading Volume
VTGN
VistaGen Therapeutics
1.8123 of 5 stars
$1.96
-2.0%
N/A-43.7%$58.31M$490K-1.1840

Related Companies and Tools


This page (NASDAQ:LPTX) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners